c19early.org COVID-19 treatment researchCOVID-19 treatments

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Innovation Pharmaceuticals, NCT04784897, NCT04784897, Jul 2021
Late treatmentDouble-blind RCT · NCT04784897 · 120 patients · USA
Brilacidin for COVID-19
Innovation Pharmaceuticals NCT04784897 · July 2021
Trial underpowered to detect differences
RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
OutcomeImprovementEffect · pTreatmentControl
risk of death 0.0% lower · RR 1.00 · p = 1.00 0.0% lowerRR 1.00p = 1.00 4 of 60 (6.7%) 4 of 60 (6.7%) treatment 4 of 60 (6.7%), control 4 of 60 (6.7%)day 60
risk of death 33.3% higher · RR 1.33 · p = 1.00 33.3% higherRR 1.33p = 1.00 4 of 60 (6.7%) 3 of 60 (5.0%) treatment 4 of 60 (6.7%), control 3 of 60 (5.0%)day 28
risk of death/intubation 33.3% higher · RR 1.33 · p = 1.00 33.3% higherRR 1.33p = 1.00 4 of 60 (6.7%) 3 of 60 (5.0%) treatment 4 of 60 (6.7%), control 3 of 60 (5.0%)day 29
risk of no recovery 20.0% higher · RR 1.20 · p = 1.00 20.0% higherRR 1.20p = 1.00 6 of 60 (10.0%) 5 of 60 (8.3%) treatment 6 of 60 (10.0%), control 5 of 60 (8.3%)day 29
recovery time 8.3% higher · relative time 1.08 · p = 0.54 8.3% higherrelative time 1.08p = 0.54 13.0 [11.0-14.0] n=44 12.0 [9.0-14.0] n=60 treatment 13.0 [11.0-14.0] n=44, control 12.0 [9.0-14.0] n=60

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Innovation Pharmaceuticals et al., 30 Jul 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04784897 (history). Contact: info@ipharminc.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective